The next generation of seniors will be more obese and have more diabetes, a study finds. (NPR)
Speaking of diabetes, a host of groups agree that obesity surgery can help stop it. (Associated Press)
Ed Silverman @Pharmalot reports that the FDA will not issue a decision on Sarepta Pharmaceuticals' drug for Duchenne muscular dystrophy. This marks the second time that the FDA has put off a decision on the drug.
FDA advisors voted in favor of approving a patent foramen ovale (PFO) occluder device to prevent strokes, despite doubts raised by the agency; MedPage Today has the story.
Want to join a clinical trial? You're in the minority, a survey finds. (HealthDay News)
More men are choosing active surveillance rather than treatment for prostate cancer. (The New York Times)
Your fitness tracker may be good at tracking steps, but calories? Not so much. (Washington Post)
Congress is asking automakers to explain why some car seats are failing. (CBS News)
Spiking drinks is becoming a problem on college campuses. (U.S. News)
Lilly is touting a new drug that it claims could lessen need for opioids. (Reuters)
"National Cancer Moonshot Summit" hosted by Vice President Biden planned for June. (AP)
From the Charlotte's Web bureau: "Some spider webs" can heal. (CNN)
Morning Break is a daily guide to what's new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: MPT_editorial@everydayhealthinc.com.